
    
      To evaluate the incidence of adverse events and clinical laboratory abnormalities defined as
      dose-limiting toxicity in subjects with metastatic non-squamous non-small cell lung cancer
      (NSCLC) treated with AMG 386 in combination with pemetrexed and carboplatin
    
  